{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+comparator+%28SC%29", "query": { "intervention": "Placebo comparator (SC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1410, "total_pages": 141, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+comparator+%28SC%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T21:12:04.522Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02696798", "title": "A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spondyloarthritis" ], "interventions": [ { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2016-04-12", "completion_date": "2019-05-03", "has_results": true, "last_update_posted_date": "2020-06-17", "last_synced_at": "2026-09-16T21:12:04.522Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Escondido, California • Huntington Beach, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02696798" }, { "nct_id": "NCT01544998", "title": "Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Congestive Heart Failure" ], "interventions": [ { "name": "Nesiritide", "type": "DRUG" }, { "name": "Tadalafil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Saline load", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "21 Years to 90 Years" }, "enrollment_count": 43, "start_date": "2012-02", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2018-03-22", "last_synced_at": "2026-09-16T21:12:04.522Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01544998" }, { "nct_id": "NCT04455750", "title": "A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Rucaparib camsylate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 61, "start_date": "2021-10-14", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-16T21:12:04.522Z", "location_count": 414, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 298 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04455750" }, { "nct_id": "NCT05507450", "title": "Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dengue Disease", "Dengue Virus" ], "interventions": [ { "name": "V181 High-Potency Level", "type": "BIOLOGICAL" }, { "name": "V181 Mid-Potency Level", "type": "BIOLOGICAL" }, { "name": "V181 Low-Potency Level", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 1271, "start_date": "2022-09-07", "completion_date": "2024-05-07", "has_results": true, "last_update_posted_date": "2025-05-09", "last_synced_at": "2026-09-16T21:12:04.522Z", "location_count": 6, "location_summary": "San Diego, California • Miami, Florida • Rochester, New York + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Rochester", "state": "New York" }, { "city": "Galveston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05507450" }, { "nct_id": "NCT06252220", "title": "First in Human Study in Subjects With Obesity, But Otherwise Healthy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "DA-1726", "type": "DRUG" }, { "name": "Placebo to DA-1726", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeuroBo Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 139, "start_date": "2024-03-25", "completion_date": "2026-11-09", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-09-16T21:12:04.522Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06252220" }, { "nct_id": "NCT02585778", "title": "Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" }, { "name": "Antihyperglycemic Drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 517, "start_date": "2015-10-23", "completion_date": "2017-04-03", "has_results": true, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-09-16T21:12:04.522Z", "location_count": 29, "location_summary": "Encino, California • Fresno, California • Oakland, California + 25 more", "locations": [ { "city": "Encino", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Loveland", "state": "Colorado" }, { "city": "Atlantis", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02585778" }, { "nct_id": "NCT02604433", "title": "An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Erythrocyte Transfusion", "Beta-Thalassemia" ], "interventions": [ { "name": "Luspatercept", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 336, "start_date": "2016-05-02", "completion_date": "2021-01-05", "has_results": true, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-09-16T21:12:04.522Z", "location_count": 6, "location_summary": "Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02604433" }, { "nct_id": "NCT06264310", "title": "To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure", "Worsening Heart Failure (WHF)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "R2R01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "River 2 Renal Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2024-03-01", "completion_date": "2024-11-25", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-09-16T21:12:04.522Z", "location_count": 8, "location_summary": "Fairhope, Alabama • Fort Meyers, Florida • Hialeah, Florida + 5 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Fort Meyers", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Inverness", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06264310" }, { "nct_id": "NCT02891226", "title": "A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Mirikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 191, "start_date": "2016-12-14", "completion_date": "2021-02-05", "has_results": true, "last_update_posted_date": "2022-08-30", "last_synced_at": "2026-09-16T21:12:04.522Z", "location_count": 44, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Garden Grove, California + 38 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Garden Grove", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02891226" }, { "nct_id": "NCT04981717", "title": "A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Allergic Rhinitis Due to Cat Allergy" ], "interventions": [ { "name": "REGN1908-1909", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 446, "start_date": "2021-07-30", "completion_date": "2023-04-24", "has_results": true, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-09-16T21:12:04.522Z", "location_count": 42, "location_summary": "Mission Viejo, California • Riverside, California • Rolling Hills Estates, California + 39 more", "locations": [ { "city": "Mission Viejo", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04981717" } ] }